Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models.

Autor: Tucker ER; Pediatric Tumour Biology and Therapeutics Team, Centre for Paediatric Oncology Experimental Medicine, Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom., Jiménez I; SiRIC RTOP (Recherche Translationelle en Oncologie Pédiatrique), Translational Research Department, Institut Curie Research Center, PSL Research University, Institut Curie, Paris, France.; INSERM U830, Equipe Labellisée Ligue contre le Cancer, PSL Research University, Institut Curie Research Center, Paris, France., Chen L; Wolfson Childhood Cancer Research Centre, Translational & Clinical Research Institute, Newcastle Centre for Cancer, Newcastle University, Newcastle upon Tyne, United Kingdom., Bellini A; SiRIC RTOP (Recherche Translationelle en Oncologie Pédiatrique), Translational Research Department, Institut Curie Research Center, PSL Research University, Institut Curie, Paris, France.; INSERM U830, Equipe Labellisée Ligue contre le Cancer, PSL Research University, Institut Curie Research Center, Paris, France., Gorrini C; Pediatric Tumour Biology and Therapeutics Team, Centre for Paediatric Oncology Experimental Medicine, Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom., Calton E; Pediatric Tumour Biology and Therapeutics Team, Centre for Paediatric Oncology Experimental Medicine, Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom., Gao Q; Pediatric Tumour Biology and Therapeutics Team, Centre for Paediatric Oncology Experimental Medicine, Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom., Che H; Pediatric Tumour Biology and Therapeutics Team, Centre for Paediatric Oncology Experimental Medicine, Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom., Poon E; Pediatric Tumour Biology and Therapeutics Team, Centre for Paediatric Oncology Experimental Medicine, Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom., Jamin Y; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, United Kingdom., Martins Da Costa B; Pediatric Tumour Biology and Therapeutics Team, Centre for Paediatric Oncology Experimental Medicine, Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom., Barker K; Pediatric Tumour Biology and Therapeutics Team, Centre for Paediatric Oncology Experimental Medicine, Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom., Shrestha S; Pediatric Tumour Biology and Therapeutics Team, Centre for Paediatric Oncology Experimental Medicine, Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom., Hutchinson JC; Department of Histopathology, Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom., Dhariwal S; Wolfson Childhood Cancer Research Centre, Translational & Clinical Research Institute, Newcastle Centre for Cancer, Newcastle University, Newcastle upon Tyne, United Kingdom., Goodman A; Newcastle Genetics Laboratory, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, United Kingdom., Del Nery E; Department of Translational Research, The Biophenics High-Content Screening Laboratory, PSL Research University, PICT-IBiSa, Institut Curie Research Center, Paris, France., Gestraud P; Bioinformatics platform, INSERM U900, PSL Research University, Institut Curie Research Center, Paris, France., Bhalshankar J; SiRIC RTOP (Recherche Translationelle en Oncologie Pédiatrique), Translational Research Department, Institut Curie Research Center, PSL Research University, Institut Curie, Paris, France.; INSERM U830, Equipe Labellisée Ligue contre le Cancer, PSL Research University, Institut Curie Research Center, Paris, France., Iddir Y; SiRIC RTOP (Recherche Translationelle en Oncologie Pédiatrique), Translational Research Department, Institut Curie Research Center, PSL Research University, Institut Curie, Paris, France.; INSERM U830, Equipe Labellisée Ligue contre le Cancer, PSL Research University, Institut Curie Research Center, Paris, France., Saberi-Ansari E; SiRIC RTOP (Recherche Translationelle en Oncologie Pédiatrique), Translational Research Department, Institut Curie Research Center, PSL Research University, Institut Curie, Paris, France.; INSERM U830, Equipe Labellisée Ligue contre le Cancer, PSL Research University, Institut Curie Research Center, Paris, France., Saint-Charles A; SiRIC RTOP (Recherche Translationelle en Oncologie Pédiatrique), Translational Research Department, Institut Curie Research Center, PSL Research University, Institut Curie, Paris, France.; INSERM U830, Equipe Labellisée Ligue contre le Cancer, PSL Research University, Institut Curie Research Center, Paris, France., Geoerger B; Gustave Roussy Cancer Center, Department of Pediatric and Adolescent Oncology, Université Paris-Saclay, Villejuif, France., Marques Da Costa ME; Gustave Roussy Cancer Center, Department of Pediatric and Adolescent Oncology, Université Paris-Saclay, Villejuif, France., Pierre-Eugène C; INSERM U830, Equipe Labellisée Ligue contre le Cancer, PSL Research University, Institut Curie Research Center, Paris, France., Janoueix-Lerosey I; INSERM U830, Equipe Labellisée Ligue contre le Cancer, PSL Research University, Institut Curie Research Center, Paris, France., Decaudin D; Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University, Paris, France.; Department of Medical Oncology, Institut Curie, Paris, France., Nemati F; Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, PSL University, Paris, France., Carcaboso AM; Hospital Sant Joan de Déu, Barcelona, Spain., Surdez D; INSERM U830, Equipe Labellisée Ligue contre le Cancer, PSL Research University, Institut Curie Research Center, Paris, France.; Balgrist University Hospital, Faculty of Medicine, University of Zurich (UZH), Zurich, Switzerland., Delattre O; INSERM U830, Equipe Labellisée Ligue contre le Cancer, PSL Research University, Institut Curie Research Center, Paris, France., George SL; Pediatric Tumour Biology and Therapeutics Team, Centre for Paediatric Oncology Experimental Medicine, Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom., Chesler L; Pediatric Tumour Biology and Therapeutics Team, Centre for Paediatric Oncology Experimental Medicine, Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom., Tweddle DA; Wolfson Childhood Cancer Research Centre, Translational & Clinical Research Institute, Newcastle Centre for Cancer, Newcastle University, Newcastle upon Tyne, United Kingdom., Schleiermacher G; SiRIC RTOP (Recherche Translationelle en Oncologie Pédiatrique), Translational Research Department, Institut Curie Research Center, PSL Research University, Institut Curie, Paris, France.; INSERM U830, Equipe Labellisée Ligue contre le Cancer, PSL Research University, Institut Curie Research Center, Paris, France.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Apr 03; Vol. 29 (7), pp. 1317-1331.

Targeting MYCN and ALK in resistant and relapsing neuroblastoma.

Autor: Tucker ER; Division of Clinical Studies, The Institute of Cancer Research, Sutton, SM2 5NG, UK., Poon E; Division of Clinical Studies, The Institute of Cancer Research, Sutton, SM2 5NG, UK., Chesler L; Division of Clinical Studies, The Institute of Cancer Research, Sutton, SM2 5NG, UK.

Publikováno v: Cancer drug resistance (Alhambra, Calif.) [Cancer Drug Resist] 2019 Sep 19; Vol. 2 (3), pp. 803-812. Date of Electronic Publication: 2019 Sep 19 (Print Publication: 2019).

Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project.

Autor: Moreno L; a Paediatric Phase I-II Clinical Trials Unit, Paediatric Haematology & Oncology , Hospital Niño Jesus , Madrid , Spain.; b Instituto de Investigación Sanitaria La Princesa , Madrid , Spain.; c Paediatric Drug Development, Children and Young People's Unit , Royal Marsden Hospital , London , UK., Caron H; d Emma Children's Hospital , Amsterdam , Netherlands.; e Hoffman-La Roche , Basel , Switzerland., Geoerger B; f Department of Paediatric and Adolescent Oncology , Institut Gustave Roussy , Villejuif , France., Eggert A; g Department of Pediatric Oncology and Hematology , Charite University Hospital , Berlin , Germany., Schleiermacher G; h Department of Paediatric, Adolescents and Young Adults Oncology and INSERM U830 , Institut Curie , Paris , France., Brock P; i Department Paediatric Oncology , Great Ormond Street Hospital , London , UK., Valteau-Couanet D; f Department of Paediatric and Adolescent Oncology , Institut Gustave Roussy , Villejuif , France., Chesler L; c Paediatric Drug Development, Children and Young People's Unit , Royal Marsden Hospital , London , UK.; j Division of Clinical Studies , Institute of Cancer Research , London , UK., Schulte JH; g Department of Pediatric Oncology and Hematology , Charite University Hospital , Berlin , Germany., De Preter K; k Centre for Medical Genetic , Ghent University , Ghent , Belgium., Molenaar J; l Princess Maxima Center for Pediatric Oncology , University of Amsterdam , Amsterdam , Netherlands., Schramm A; m Department of Pediatric Oncology , University of Essen , Essen , Germany., Eilers M; n Theodor Boveri Institute and Comprehensive Cancer Center Mainfranken, Biocenter , University of Wurzburg , Wurzburg , Germany., Van Maerken T; k Centre for Medical Genetic , Ghent University , Ghent , Belgium., Johnsen JI; o Department of Women's and Children's Health , Karolinska Institute , Stockholm , Sweden., Garrett M; p School of Biosciences , University of Kent , Canterbury , UK., George SL; c Paediatric Drug Development, Children and Young People's Unit , Royal Marsden Hospital , London , UK.; j Division of Clinical Studies , Institute of Cancer Research , London , UK., Tweddle DA; q Wolfson Childhood Cancer Research Centre , Newcastle University , Newcastle , UK., Kogner P; o Department of Women's and Children's Health , Karolinska Institute , Stockholm , Sweden., Berthold F; r Department of Pediatric Oncology and Hematology , University of Cologne , Cologne , Germany., Koster J; l Princess Maxima Center for Pediatric Oncology , University of Amsterdam , Amsterdam , Netherlands., Barone G; c Paediatric Drug Development, Children and Young People's Unit , Royal Marsden Hospital , London , UK.; j Division of Clinical Studies , Institute of Cancer Research , London , UK., Tucker ER; c Paediatric Drug Development, Children and Young People's Unit , Royal Marsden Hospital , London , UK.; j Division of Clinical Studies , Institute of Cancer Research , London , UK., Marshall L; c Paediatric Drug Development, Children and Young People's Unit , Royal Marsden Hospital , London , UK.; j Division of Clinical Studies , Institute of Cancer Research , London , UK., Herold R; s European Medicines Agency , London , UK., Sterba J; t Masaryk University, University Hospital , Brno , Czech Republic.; u Department of Pediatric Oncology , International Clinical Research Center, St. Anne's University Hospital , Brno , Czech Republic.; v RECAMO, Masaryk Memorial Cancer Centre , Brno , Czech Republic., Norga K; w Pediatric Hematology/Oncology Unit , Antwerp University Hospital , Antwerp , Belgium., Vassal G; x Department of Clinical Research, Gustave Roussy , Paris-Sud University , Paris , France., Pearson AD; c Paediatric Drug Development, Children and Young People's Unit , Royal Marsden Hospital , London , UK.; j Division of Clinical Studies , Institute of Cancer Research , London , UK.

Publikováno v: Expert opinion on drug discovery [Expert Opin Drug Discov] 2017 Aug; Vol. 12 (8), pp. 801-811. Date of Electronic Publication: 2017 Jun 26.

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.

Autor: Guan J; Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg SE-405 30, Sweden., Tucker ER; Division of Clinical Studies Cancer Therapeutics, The Institute of Cancer Research, London and Royal Marsden NHS Foundation Trust, Sutton SM2 5NG, UK., Wan H; Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg SE-405 30, Sweden., Chand D; Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg SE-405 30, Sweden., Danielson LS; Division of Clinical Studies Cancer Therapeutics, The Institute of Cancer Research, London and Royal Marsden NHS Foundation Trust, Sutton SM2 5NG, UK., Ruuth K; Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg SE-405 30, Sweden Department of Molecular Biology, Building 6L, Umeå University, Umeå 901 87, Sweden., El Wakil A; Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg SE-405 30, Sweden Department of Molecular Biology, Building 6L, Umeå University, Umeå 901 87, Sweden., Witek B; Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg SE-405 30, Sweden Department of Molecular Biology, Building 6L, Umeå University, Umeå 901 87, Sweden., Jamin Y; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London and Royal Marsden NHS Foundation Trust, Sutton SM2 5NG, UK., Umapathy G; Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg SE-405 30, Sweden., Robinson SP; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London and Royal Marsden NHS Foundation Trust, Sutton SM2 5NG, UK., Johnson TW; La Jolla Laboratories, Pfizer Worldwide Research and Development, San Diego, CA 92121, USA., Smeal T; La Jolla Laboratories, Pfizer Worldwide Research and Development, San Diego, CA 92121, USA., Martinsson T; Department of Clinical Genetics, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg SE-405 30, Sweden., Chesler L; Division of Clinical Studies Cancer Therapeutics, The Institute of Cancer Research, London and Royal Marsden NHS Foundation Trust, Sutton SM2 5NG, UK louis.chesler@icr.ac.uk ruth.palmer@gu.se bengt.hallberg@gu.se., Palmer RH; Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg SE-405 30, Sweden louis.chesler@icr.ac.uk ruth.palmer@gu.se bengt.hallberg@gu.se., Hallberg B; Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg SE-405 30, Sweden louis.chesler@icr.ac.uk ruth.palmer@gu.se bengt.hallberg@gu.se.

Publikováno v: Disease models & mechanisms [Dis Model Mech] 2016 Sep 01; Vol. 9 (9), pp. 941-52. Date of Electronic Publication: 2016 Jul 07.

Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma.

Autor: Jamin Y; Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, 15 Cotswold Road, Sutton, Surrey SM2 5NG, England. Yann.Jamin@icr.ac.uk, Tucker ER, Poon E, Popov S, Vaughan L, Boult JK, Webber H, Hallsworth A, Baker LC, Jones C, Koh DM, Pearson AD, Chesler L, Robinson SP

Publikováno v: Radiology [Radiology] 2013 Jan; Vol. 266 (1), pp. 130-40. Date of Electronic Publication: 2012 Nov 20.